Targeting Stat3 induces senescence in tumor cells and elicits prophylactic and therapeutic immune responses against breast cancer growth mediated by NK cells and CD4 + T cells

Journal of Immunology

Volumn 189, Issue 3, 2012, Pages 1162-1172

  Tkach, Mercedes ^a   Coria, Lorena ^b   Rosemblit, Cinthia ^a   Rivas, Martín A ^a,d   Proietti, Cecilia J ^a   Flaqué, María Celeste Díaz ^a   Beguelin, Wendy ^a   Frahm, Isabel ^c   Charreau, Eduardo H ^a   Cassataro, Juliana ^b   Elizalde, Patricia V ^a   Schillaci, Roxana ^a  

^a Consejo Nacional de Investigaciones Científicas Y Técnicas de Argentina ^*  (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c Sanatorio Mater Dei   (Argentina)

^d VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GESTAGEN; PHENYLALANINE; STAT3 PROTEIN; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CELL AGING; CELL ASSAY; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; FEMALE; GENETIC TRANSFECTION; IMMUNE RESPONSE; IN VIVO STUDY; IRRADIATION; LUNG METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL AGING; CELL LINE, TUMOR; CHEMOKINES; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GENE TARGETING; KILLER CELLS, NATURAL; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; MICE, NUDE; PRIMARY CELL CULTURE; STAT3 TRANSCRIPTION FACTOR;

EID: 84864134596     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102538     Document Type: Article

References (41)

1. Bromberg, J. F., M. H. Wrzeszczynska, G. Devgan, Y. Zhao, R. G. Pestell, C. Albanese, and J. E. Darnell, Jr. 1999. Stat3 as an oncogene. Cell 98: 295-303. (Pubitemid 29380565)
2. Buettner, R., L. B. Mora, and R. Jove. 2002. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 8: 945-954. (Pubitemid 35177340)
3. Rabinovich, G. A., D. Gabrilovich, and E. M. Sotomayor. 2007. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25: 267-296. (Pubitemid 46697910)
4. Yu, H., M. Kortylewski, and D. Pardoll. 2007. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7: 41-51. (Pubitemid 46020826)
5. Kortylewski, M., and H. Yu. 2008. Role of Stat3 in suppressing anti-tumor immunity. Curr. Opin. Immunol. 20: 228-233.
6. Wang, T., G. Niu, M. Kortylewski, L. Burdelya, K. Shain, S. Zhang, R. Bhattacharya, D. Gabrilovich, R. Heller, D. Coppola, et al. 2004. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10: 48-54. (Pubitemid 38524698)
7. Bowman, T., R. Garcia, J. Turkson, and R. Jove. 2000. STATs in oncogenesis. Oncogene 19: 2474-2488. (Pubitemid 30339203)
8. Yu, H., and R. Jove. 2004. The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 4: 97-105. (Pubitemid 38198738)
9. Gritsko, T., A. Williams, J. Turkson, S. Kaneko, T. Bowman, M. Huang, S. Nam, I. Eweis, N. Diaz, D. Sullivan, et al. 2006. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. 12: 11-19. (Pubitemid 43166170)
10. Real, P. J., A. Sierra, A. De Juan, J. C. Segovia, J. M. Lopez-Vega, and J. L. Fernandez-Luna. 2002. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21: 7611-7618. (Pubitemid 35398808)
11. Wu, C. H., J. van Riggelen, A. Yetil, A. C. Fan, P. Bachireddy, and D.W. Felsher. 2007. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc. Natl. Acad. Sci. USA 104: 13028-13033. (Pubitemid 351737587)
12. + T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18: 485-498.
13. Rivas, M. A., R. P. Carnevale, C. J. Proietti, C. Rosemblit, W. Beguelin, M. Salatino, E. H. Charreau, I. Frahm, S. Sapia, P. Brouckaert, et al. 2008. TNFαacting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-κB-dependent pathways. Exp. Cell Res. 314: 509-529.
14. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. 1996. Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC.
15. Lanari, C., C. A. Lamb, V. T. Fabris, L. A. Helguero, R. Soldati, M. C. Bottino, S. Giulianelli, J. P. Cerliani, V. Wargon, and A. Molinolo. 2009. The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr. Relat. Cancer 16: 333-350.
16. Salatino, M., R. Schillaci, C. J. Proietti, R. Carnevale, I. Frahm, A. A. Molinolo, A. Iribarren, E. H. Charreau, and P. V. Elizalde. 2004. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity. Oncogene 23: 5161-5174. (Pubitemid 38980349)
17. Rivas, M. A., M. Tkach, W. Beguelin, C. J. Proietti, C. Rosemblit, E. H. Charreau, P. V. Elizalde, and R. Schillaci. 2010. Transactivation of ErbB-2 induced by tumor necrosis factor α promotes NF-κB activation and breast cancer cell proliferation. Breast Cancer Res. Treat. 122: 111-124.
18. Bromberg, J. F., C. M. Horvath, D. Besser, W. W. Lathem, and J. E. Darnell, Jr. 1998. Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol. 18: 2553-2558. (Pubitemid 28183425)
19. Proietti, C., M. Salatino, C. Rosemblit, R. Carnevale, A. Pecci, A. R. Kornblihtt, A. A. Molinolo, I. Frahm, E. H. Charreau, R. Schillaci, and P. V. Elizalde. 2005. Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Mol. Cell. Biol. 25: 4826-4840. (Pubitemid 40781085)
20. Schillaci, R., M. Salatino, J. Cassataro, C. J. Proietti, G. H. Giambartolomei, M. A. Rivas, R. P. Carnevale, E. H. Charreau, and P. V. Elizalde. 2006. Immunization with murine breast cancer cells treated with antisense oligodeoxynucleotides to type I insulin-like growth factor receptor induced an antitumoral effect mediated by a CD8+ response involving Fas/Fas ligand cytotoxic pathway. J. Immunol. 176: 3426-3437. (Pubitemid 43363990)
21. Dimri, G. P., X. Lee, G. Basile, M. Acosta, G. Scott, C. Roskelley, E. E. Medrano, M. Linskens, I. Rubelj, O. Pereira-Smith, et al. 1995. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 92: 9363-9367.
22. Dexter, D. L., H. M. Kowalski, B. A. Blazar, Z. Fligiel, R. Vogel, and G. H. Heppner. 1978. Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res. 38: 3174-3181. (Pubitemid 9031291)
23. Aslakson, C. J., and F. R. Miller. 1992. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52: 1399-1405.
24. Ling, X., and R. B. Arlinghaus. 2005. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res. 65: 2532-2536. (Pubitemid 40490046)
25. Blaskovich, M. A., J. Sun, A. Cantor, J. Turkson, R. Jove, and S. M. Sebti. 2003. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 63: 1270-1279. (Pubitemid 36348705)
26. Burdelya, L., M. Kujawski, G. Niu, B. Zhong, T. Wang, S. Zhang, M. Kortylewski, K. Shain, H. Kay, J. Djeu, et al. 2005. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J. Immunol. 174: 3925-3931. (Pubitemid 40395966)
27. Scuto, A., M. Kujawski, C. Kowolik, L. Krymskaya, L. Wang, L. M. Weiss, D. Digiusto, H. Yu, S. Forman, and R. Jove. 2011. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res. 71: 3182-3188.
28. Nefedova, Y., P. Cheng, D. Gilkes, M. Blaskovich, A. A. Beg, S. M. Sebti, and D. I. Gabrilovich. 2005. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J. Immunol. 175: 4338-4346. (Pubitemid 41361968)
29. Müller-Hermelink, N., H. Braumüller, B. Pichler, T. Wieder, R. Mailhammer, K. Schaak, K. Ghoreschi, A. Yazdi, R. Haubner, C. A. Sander, et al. 2008. TNFR1 signaling and IFN-γ signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 13: 507-518. (Pubitemid 351763899)
30. Wendel, M., I. E. Galani, E. Suri-Payer, and A. Cerwenka. 2008. Natural killer cell accumulation in tumors is dependent on IFN-γ and CXCR3 ligands. Cancer Res. 68: 8437-8445.
31. Arenberg, D. A., S. L. Kunkel, P. J. Polverini, S. B. Morris, M. D. Burdick, M. C. Glass, D. T. Taub, M. D. Iannettoni, R. I. Whyte, and R. M. Strieter. 1996. Interferon-γ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med. 184: 981-992.
32. Pegram, H. J., D. M. Andrews, M. J. Smyth, P. K. Darcy, and M. H. Kershaw. 2011. Activating and inhibitory receptors of natural killer cells. Immunol. Cell Biol. 89: 216-224.
33. Diefenbach, A., A. M. Jamieson, S. D. Liu, N. Shastri, and D. H. Raulet. 2000. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat. Immunol. 1: 119-126.
34. Takaki, R., Y. Hayakawa, A. Nelson, P. V. Sivakumar, S. Hughes, M. J. Smyth, and L. L. Lanier. 2005. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J. Immunol. 175: 2167-2173. (Pubitemid 41113822)
35. Adris, S., E. Chuluyan, A. Bravo, M. Berenstein, S. Klein, M. Jasnis, C. Carbone, Y. Chernajovsky, and O. L. Podhajcer. 2000. Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells. Cancer Res. 60: 6696-6703.
36. Li, Y., H. Zeng, R. H. Xu, B. Liu, and Z. Li. 2009. Vaccination with human pluripotent stem cells generates a broad spectrum of immunological and clinical responses against colon cancer. Stem Cells 27: 3103-3111.
37. Olkhanud, P. B., D. Baatar, M. Bodogai, F. Hakim, R. Gress, R. L. Anderson, J. Deng, M. Xu, S. Briest, and A. Biragyn. 2009. Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res. 69: 5996-6004.
38. Soerjomataram, I., M. W. Louwman, J. G. Ribot, J. A. Roukema, and J. W. Coebergh. 2008. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res. Treat. 107: 309-330. (Pubitemid 351172108)
39. Rabbani, S. A., and A. P. Mazar. 2007. Evaluating distant metastases in breast cancer: from biology to outcomes. Cancer Metastasis Rev. 26: 663-674. (Pubitemid 350115115)
40. Kortylewski, M., M. Kujawski, T. Wang, S. Wei, S. Zhang, S. Pilon-Thomas, G. Niu, H. Kay, J. Mulé, W. G. Kerr, et al. 2005. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11: 1314-1321. (Pubitemid 41752912)
41. Liu, L., S. Nam, Y. Tian, F. Yang, J. Wu, Y. Wang, A. Scuto, P. Polychronopoulos, P. Magiatis, L. Skaltsounis, et al. 2011. 6-Bromoindirubin- 3′-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. Cancer Res. 71: 3972-3979.